ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-39T5731
Home | Market Reports | Health| Health Conditions| Neurological Conditions
Global Attention deficit Hyperactivity Disorder ADHD Therapeutics Market Insights Forecast to 2028
BUY CHAPTERS

Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Research Report 2025

Code: QYRE-Auto-39T5731
Report
September 2025
Pages:81
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Pfizer Inc
GSK
Eli Lilly
Novartis
Johnson & Johnson
Mallinckrodt plc
Hisamitsu
UCB
Takeda
Purdue Pharma
Impax Laboratories
Johnson & Johnson

Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market

The global market for Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Attention-deficit/hyperactivity disorder (ADHD) is a disorder marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development.
Inattention means a person wanders off task, lacks persistence, has difficulty sustaining focus, and is disorganized; and these problems are not due to defiance or lack of comprehension.
Hyperactivity means a person seems to move about constantly, including in situations in which it is not appropriate; or excessively fidgets, taps, or talks. In adults, it may be extreme restlessness or wearing others out with constant activity.
Impulsivity means a person makes hasty actions that occur in the moment without first thinking about them and that may have a high potential for harm, or a desire for immediate rewards or inability to delay gratification. An impulsive person may be socially intrusive and excessively interrupt others or make important decisions without considering the long-term consequences.
North American market for Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics in Pediatric and Adolescents is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics include Pfizer, GSK, Eli Lilly, Novartis, Johnson & Johnson, Mallinckrodt, Hisamitsu, UCB, Takeda, Purdue Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics.
The Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Report

Report Metric Details
Report Name Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market
Segment by Type
  • Stimulants
  • Non-stimulants
Segment by Application
  • Pediatric and Adolescents
  • Adults
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Pfizer, GSK, Eli Lilly, Novartis, Johnson & Johnson, Mallinckrodt, Hisamitsu, UCB, Takeda, Purdue Pharma, Impax Laboratories
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market report?

Ans: The main players in the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market are Pfizer, GSK, Eli Lilly, Novartis, Johnson & Johnson, Mallinckrodt, Hisamitsu, UCB, Takeda, Purdue Pharma, Impax Laboratories

What are the Application segmentation covered in the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market report?

Ans: The Applications covered in the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market report are Pediatric and Adolescents, Adults

What are the Type segmentation covered in the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market report?

Ans: The Types covered in the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market report are Stimulants, Non-stimulants

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Stimulants
1.2.3 Non-stimulants
1.3 Market by Application
1.3.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pediatric and Adolescents
1.3.3 Adults
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Perspective (2020-2031)
2.2 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Growth Trends by Region
2.2.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Dynamics
2.3.1 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Industry Trends
2.3.2 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Drivers
2.3.3 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Challenges
2.3.4 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Players by Revenue
3.1.1 Global Top Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue
3.4 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Concentration Ratio
3.4.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue in 2024
3.5 Global Key Players of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Head office and Area Served
3.6 Global Key Players of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics, Product and Application
3.7 Global Key Players of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Breakdown Data by Type
4.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Type (2026-2031)
5 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Breakdown Data by Application
5.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2020-2031)
6.2 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2020-2025)
6.4 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2020-2031)
7.2 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2020-2025)
7.4 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2020-2031)
9.2 Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.1.4 Pfizer Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025)
11.1.5 Pfizer Recent Development
11.2 GSK
11.2.1 GSK Company Details
11.2.2 GSK Business Overview
11.2.3 GSK Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.2.4 GSK Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025)
11.2.5 GSK Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Details
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.3.4 Eli Lilly Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025)
11.3.5 Eli Lilly Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.4.4 Novartis Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025)
11.4.5 Novartis Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Details
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.5.4 Johnson & Johnson Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025)
11.5.5 Johnson & Johnson Recent Development
11.6 Mallinckrodt
11.6.1 Mallinckrodt Company Details
11.6.2 Mallinckrodt Business Overview
11.6.3 Mallinckrodt Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.6.4 Mallinckrodt Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025)
11.6.5 Mallinckrodt Recent Development
11.7 Hisamitsu
11.7.1 Hisamitsu Company Details
11.7.2 Hisamitsu Business Overview
11.7.3 Hisamitsu Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.7.4 Hisamitsu Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025)
11.7.5 Hisamitsu Recent Development
11.8 UCB
11.8.1 UCB Company Details
11.8.2 UCB Business Overview
11.8.3 UCB Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.8.4 UCB Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025)
11.8.5 UCB Recent Development
11.9 Takeda
11.9.1 Takeda Company Details
11.9.2 Takeda Business Overview
11.9.3 Takeda Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.9.4 Takeda Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025)
11.9.5 Takeda Recent Development
11.10 Purdue Pharma
11.10.1 Purdue Pharma Company Details
11.10.2 Purdue Pharma Business Overview
11.10.3 Purdue Pharma Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.10.4 Purdue Pharma Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025)
11.10.5 Purdue Pharma Recent Development
11.11 Impax Laboratories
11.11.1 Impax Laboratories Company Details
11.11.2 Impax Laboratories Business Overview
11.11.3 Impax Laboratories Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.11.4 Impax Laboratories Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025)
11.11.5 Impax Laboratories Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Pfizer Inc
GSK
Eli Lilly
Novartis
Johnson & Johnson
Mallinckrodt plc
Hisamitsu
UCB
Takeda
Purdue Pharma
Impax Laboratories
Johnson & Johnson
List of Tables
 Table 1. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Stimulants
 Table 3. Key Players of Non-stimulants
 Table 4. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 5. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region (2020-2025) & (US$ Million)
 Table 7. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Region (2020-2025)
 Table 8. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 9. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Region (2026-2031)
 Table 10. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Trends
 Table 11. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Drivers
 Table 12. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Challenges
 Table 13. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Restraints
 Table 14. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Players (2020-2025) & (US$ Million)
 Table 15. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Players (2020-2025)
 Table 16. Global Top Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics as of 2024)
 Table 17. Ranking of Global Top Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Companies by Revenue (US$ Million) in 2024
 Table 18. Global 5 Largest Players Market Share by Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (CR5 and HHI) & (2020-2025)
 Table 19. Global Key Players of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics, Headquarters and Area Served
 Table 20. Global Key Players of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics, Product and Application
 Table 21. Global Key Players of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics, Date of Enter into This Industry
 Table 22. Mergers & Acquisitions, Expansion Plans
 Table 23. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2020-2025) & (US$ Million)
 Table 24. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Type (2020-2025)
 Table 25. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 26. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Type (2026-2031)
 Table 27. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2020-2025) & (US$ Million)
 Table 28. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Application (2020-2025)
 Table 29. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 30. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Application (2026-2031)
 Table 31. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 32. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
 Table 33. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
 Table 34. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
 Table 36. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region (2020-2025) & (US$ Million)
 Table 39. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
 Table 42. Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
 Table 43. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Pfizer Company Details
 Table 47. Pfizer Business Overview
 Table 48. Pfizer Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product
 Table 49. Pfizer Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025) & (US$ Million)
 Table 50. Pfizer Recent Development
 Table 51. GSK Company Details
 Table 52. GSK Business Overview
 Table 53. GSK Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product
 Table 54. GSK Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025) & (US$ Million)
 Table 55. GSK Recent Development
 Table 56. Eli Lilly Company Details
 Table 57. Eli Lilly Business Overview
 Table 58. Eli Lilly Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product
 Table 59. Eli Lilly Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025) & (US$ Million)
 Table 60. Eli Lilly Recent Development
 Table 61. Novartis Company Details
 Table 62. Novartis Business Overview
 Table 63. Novartis Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product
 Table 64. Novartis Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025) & (US$ Million)
 Table 65. Novartis Recent Development
 Table 66. Johnson & Johnson Company Details
 Table 67. Johnson & Johnson Business Overview
 Table 68. Johnson & Johnson Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product
 Table 69. Johnson & Johnson Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025) & (US$ Million)
 Table 70. Johnson & Johnson Recent Development
 Table 71. Mallinckrodt Company Details
 Table 72. Mallinckrodt Business Overview
 Table 73. Mallinckrodt Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product
 Table 74. Mallinckrodt Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025) & (US$ Million)
 Table 75. Mallinckrodt Recent Development
 Table 76. Hisamitsu Company Details
 Table 77. Hisamitsu Business Overview
 Table 78. Hisamitsu Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product
 Table 79. Hisamitsu Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025) & (US$ Million)
 Table 80. Hisamitsu Recent Development
 Table 81. UCB Company Details
 Table 82. UCB Business Overview
 Table 83. UCB Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product
 Table 84. UCB Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025) & (US$ Million)
 Table 85. UCB Recent Development
 Table 86. Takeda Company Details
 Table 87. Takeda Business Overview
 Table 88. Takeda Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product
 Table 89. Takeda Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025) & (US$ Million)
 Table 90. Takeda Recent Development
 Table 91. Purdue Pharma Company Details
 Table 92. Purdue Pharma Business Overview
 Table 93. Purdue Pharma Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product
 Table 94. Purdue Pharma Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025) & (US$ Million)
 Table 95. Purdue Pharma Recent Development
 Table 96. Impax Laboratories Company Details
 Table 97. Impax Laboratories Business Overview
 Table 98. Impax Laboratories Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product
 Table 99. Impax Laboratories Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025) & (US$ Million)
 Table 100. Impax Laboratories Recent Development
 Table 101. Research Programs/Design for This Report
 Table 102. Key Data Information from Secondary Sources
 Table 103. Key Data Information from Primary Sources
 Table 104. Authors List of This Report


List of Figures
 Figure 1. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Picture
 Figure 2. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Type: 2024 VS 2031
 Figure 4. Stimulants Features
 Figure 5. Non-stimulants Features
 Figure 6. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2020-2031) & (US$ Million)
 Figure 7. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Application: 2024 VS 2031
 Figure 8. Pediatric and Adolescents Case Studies
 Figure 9. Adults Case Studies
 Figure 10. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Report Years Considered
 Figure 11. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 12. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Region: 2024 VS 2031
 Figure 14. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Players in 2024
 Figure 15. Global Top Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics as of 2024)
 Figure 16. The Top 10 and 5 Players Market Share by Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue in 2024
 Figure 17. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 18. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Country (2020-2031)
 Figure 19. United States Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 20. Canada Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Country (2020-2031)
 Figure 23. Germany Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. France Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. U.K. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Italy Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Russia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Nordic Countries Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Region (2020-2031)
 Figure 31. China Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Japan Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. South Korea Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Southeast Asia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. India Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Australia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Country (2020-2031)
 Figure 39. Mexico Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Brazil Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Country (2020-2031)
 Figure 43. Turkey Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Saudi Arabia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. UAE Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Pfizer Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025)
 Figure 47. GSK Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025)
 Figure 48. Eli Lilly Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025)
 Figure 49. Novartis Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025)
 Figure 50. Johnson & Johnson Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025)
 Figure 51. Mallinckrodt Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025)
 Figure 52. Hisamitsu Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025)
 Figure 53. UCB Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025)
 Figure 54. Takeda Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025)
 Figure 55. Purdue Pharma Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025)
 Figure 56. Impax Laboratories Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2020-2025)
 Figure 57. Bottom-up and Top-down Approaches for This Report
 Figure 58. Data Triangulation
 Figure 59. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

Attention Deficit Hyperactivity Disorder Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Attention Deficit and Hyperactivity Disorder Market Research Report 2025
Global Children Attention Deficit and Hyperactivity Disorder Market Research Report 2025
Global Adult Attention Deficit and Hyperactivity Disorder Market Research Report 2025
ADHD Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Attention Deficit Hyperactivity Syndrome Treatment Market Research Report 2025
Global Attention Deficit Hyperactivity Disorder ADHD Market Size Manufacturers Supply Chain Sales Channel and Clients 2024 2030
Global ADHD Drug Treatment Market Research Report 2024
Global ADHD Medications Market Insights Forecast to 2030
Global Children ADHD Treatment Market Research Report 2024
Global Attention Deficit Hyperactivity Disorder ADHD Medications Market Research Report 2024
Global Attention Deficit Hyperactivity Disorder Treatment Market Research Report 2024
Attention Deficit Hyperactivity Disorder ADHD Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
ADHD Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Anti Adhd Supplements Market Research Report 2024
Global ADHD Medication Market Research Report 2025
Global ADHD Apps Market Research Report 2024
Global ADHD Management Software Market Research Report 2024
Global Adult ADHD Treatment Market Research Report 2024
Global Pediatric ADHD Drugs Market Research Report 2025

RELATED REPORTS

Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-13Z8760
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Global Intracranial Pressure (ICP) Monitoring Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-37L4006
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Brain Disease Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-12P6151
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3X6389
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions